FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Filip Knop

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Procedures

Glucose Tolerance Test

Concepts & Ideas

Postprandial Period

Co-author Network

Publications

TOP 3
Thomas Idorn; Morten Jørgensen; Filip K Knop; Jens J Holst; Mads Hornum; Bo Feldt-Rasmussen
Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease.
Mette Gyldenløve; Filip K Knop; Tina Vilsbøll; Claus Zachariae; Lone Skov
[Psoriasis is associated with type 2 diabetes].
David P Sonne; Tina Vilsbøll; Kristine J Hare; Jens J Holst; Pernille Martens; Jens F Rehfeld; Filip K Knop
Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Filip Knop (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Thomas Idorn; Morten Jørgensen; Filip K Knop; Jens J Holst; Mads Hornum; Bo Feldt-Rasmussen
Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease.
Kidney international 2013;83(5):915-23.
2013: Mette Gyldenløve; Filip K Knop; Tina Vilsbøll; Claus Zachariae; Lone Skov
[Psoriasis is associated with type 2 diabetes].
Ugeskrift for laeger 2013;175(10):652-4.
2013: David P Sonne; Tina Vilsbøll; Kristine J Hare; Jens J Holst; Pernille Martens; Jens F Rehfeld; Filip K Knop
Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.
American journal of physiology. Gastrointestinal and liver physiology 2013;304(4):G413-9.
2013: Annesofie Faurschou; Mette Gyldenløve; Jens J Holst; Jens Pedersen; Steen S Poulsen; Lone Skov; Jacob P Thyssen; Tina Vilsbøll; Claus Zachariae; Filip K Knop
Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques.
Experimental dermatology 2013;22(2):150-2.
2013: Thomas Idorn; Tonny Jensen; Morten Jørgensen; Filip K Knop; Marsela Resuli; Karl Bang Christensen; Pernille M Hansen; Jens J Holst; Mads Hornum; Bo Feldt-Rasmussen
Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.
BMJ open 2013;3(4):.
2012: Filip K Knop; Thure Krarup; K Aaboe; J J Holst; Tina Vilsbøll; A Vølund; Sten Madsbad
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Diabetes, obesity & metabolism 2012;14(6):500-10.
2012: Asger Lund; Filip K Knop
Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.
Current medical research and opinion 2012;28(5):731-6.
2012: Katrine B Hansen; Jens J Holst; Jonatan I Bagger; Tina Vilsbøll; Filip K Knop
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
The Journal of clinical endocrinology and metabolism 2012;97(4):1363-70.
2012: N A Rhee; Tina Vilsbøll; Filip K Knop
Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes.
Diabetes, obesity & metabolism 2012;14(4):291-8.
2012: Per Kappelgaard; Filip K Knop; Katrine B Hansen; Tina Vilsbøll; Michael Larsen
Electroretinography in healthy subjects in relation to systemic glucocorticoid intake.
Documenta ophthalmologica. Advances in ophthalmology 2012;124(1):49-57.
2011: Mikkel Christensen; Jens J Holst; Louise Vedtofte; Tina Vilsbøll; Filip K Knop
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Diabetes 2011;60(12):3103-9.
2011: Annesofie Faurschou; Lone Skov; Tina Vilsbøll; Claus Zachariae; Filip K Knop
Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?
Medical hypotheses 2011;77(6):1098-101.
2011: J I Bagger; J J Holst; Filip K Knop; Tina Vilsbøll
Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
Diabetes, obesity & metabolism 2011;13(11):965-71.
2011: Katrine B Hansen; Jens J Holst; Filip K Knop; Jens F Rehfeld; Mette M Rosenkilde; Niels Wellner; Ulrik B Andersen; Thi A Diep; Harald S Hansen
2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans.
The Journal of clinical endocrinology and metabolism 2011;96(9):E1409-17.
2011: Asger Lund; Tina Vilsbøll; Jonatan I Bagger; Jens J Holst; Filip K Knop
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
American journal of physiology. Endocrinology and metabolism 2011;300(6):E1038-46.
2011: Jonatan I Bagger; Filip K Knop; Asger Lund; Henrik Vestergaard; Jens J Holst; Tina Vilsbøll
Impaired regulation of the incretin effect in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2011;96(3):737-45.
2011: Katrine B Hansen; Tina Vilsbøll; Jonatan I Bagger; Jens J Holst; Filip K Knop
Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
The Journal of clinical endocrinology and metabolism 2011;96(2):447-53.
2011: Mikkel Christensen; Jonatan I Bagger; Tina Vilsbøll; Filip K Knop
The alpha-cell as target for type 2 diabetes therapy.
The review of diabetic studies : RDS 2011;8(3):369-81.
2011: Jonatan I Bagger; Mikkel Christensen; Filip K Knop; Tina Vilsbøll
Therapy for obesity based on gastrointestinal hormones.
The review of diabetic studies : RDS 2011;8(3):339-47.
2010: Filip K Knop; Tina Vilsbøll; Steen Larsen; Sten Madsbad; Jens Juul Holst; Thure Krarup
Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis.
Regulatory peptides 2010;164(2-3):144-50.
2010: Mikkel Christensen; Filip K Knop; Tina Vilsbøll; Kasper Aaboe; Jens J Holst; Sten Madsbad; Thure Krarup
Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes.
Regulatory peptides 2010;163(1-3):96-101.
2010: Filip K Knop
Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?
American journal of physiology. Endocrinology and metabolism 2010;299(1):E10-3.
2010: Mikkel Christensen; Filip K Knop
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
Current diabetes reports 2010;10(2):124-32.
2010: K Aaboe; Filip K Knop; Tina Vilsbøll; Carolyn F Deacon; Jens Juul Holst; Sten Madsbad; Thure Krarup
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism 2010;12(4):323-33.
2010: Katrine B Hansen; Tina Vilsbøll; Filip K Knop
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.
Diabetes, metabolic syndrome and obesity : targets and therapy 2010;3():155-63.
2010: Filip K Knop; Tina Vilsbøll; Asger Lund; Thure Krarup; Jens J Holst; Mads Hornum
The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency.
JOP : Journal of the pancreas 2010;11(5):489-91.
2009: Kristine J Hare; Filip K Knop; Meena Asmar; Sten Madsbad; Carolyn F Deacon; Jens J Holst; Tina Vilsbøll
Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus.
The Journal of clinical endocrinology and metabolism 2009;94(12):4679-87.
2009: Tina Vilsbøll; Jens J Holst; Filip K Knop
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
Best practice & research. Clinical endocrinology & metabolism 2009;23(4):453-62.
2009: K B Hansen; Filip K Knop; Jens Juul Holst; Tina Vilsbøll
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
International journal of clinical practice 2009;63(8):1154-60.
2009: Filip K Knop; Tina Vilsbøll; Jens J Holst
Incretin-based therapy of type 2 diabetes mellitus.
Current protein & peptide science 2009;10(1):46-55.
2009: Kasper Aaboe; Filip K Knop; Tina Vilsboll; Aage Voelund; Simonsen Ulf; Carolyn F Deacon; Sten Madsbad; Jens Juul Holst; Thure Krarup
KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2009;94(2):603-8.
2008: Filip K Knop; Jens J Holst; Tina Vilsbøll
Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
IDrugs : the investigational drugs journal 2008;11(7):497-501.
2008: Tina Vilsbøll; Filip K Knop
Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2008;22(4):251-7.
2007: Filip K Knop; Tina Vilsbøll; Patricia V Højberg; Steen Larsen; Sten Madsbad; Jens J Holst; Thure Krarup
The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Regulatory peptides 2007;144(1-3):123-30.
2007: Filip K Knop; Tina Vilsbøll; Patricia V Højberg; Steen Larsen; Sten Madsbad; Aage Voelund; Jens J Holst; Thure Krarup
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Diabetes 2007;56(8):1951-9.
2007: Tina Vilsbøll; Filip K Knop
[Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus].
Ugeskrift for laeger 2007;169(22):2101-5.
2007: Filip K Knop; Tina Vilsbøll
[GLP-1-based treatment of type 2 diabetes mellitus].
Ugeskrift for laeger 2007;169(22):2095-9.
2007: Filip K Knop; Tina Vilsbøll; Sten Madsbad; Jens Juul Holst; Thure Krarup
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.
Diabetologia 2007;50(4):797-805.
2007: Filip K Knop; Tina Vilsbøll; Steen Larsen; Patricia V Højberg; Aage Voelund; Sten Madsbad; Jens J Holst; Thure Krarup
Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution.
American journal of physiology. Endocrinology and metabolism 2007;292(1):E324-30.
2006: Filip K Knop; Jens Aage Stauning
[The benefits of diagnostic imaging in general practice].
Ugeskrift for laeger 2006;168(8):794-8.
2005: Jonathan Schisler; Per Bo Jensen; David G Taylor; Thomas C Becker; Filip K Knop; Shiro Takekawa; Michael S German; Gordon C Weir; Danhong Lu; Raghavendra G Mirmira; Christopher B Newgard
The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(20):7297-302.
2004: Filip K Knop; Bo Pilsgaard; Søren Meisner; Peer Wille-Jørgensen
Delayed ischemic cecal perforation despite optimal decompression after placement of a self-expanding metal stent: report of a case.
Diseases of the colon and rectum 2004;47(11):1970-3.
2004: Søren Meisner; Margaret Hensler; Filip K Knop; Finn West; Peer Wille-Jørgensen
Self-expanding metal stents for colonic obstruction: experiences from 104 procedures in a single center.
Diseases of the colon and rectum 2004;47(4):444-50.
2003: Tina Vilsbøll; Filip K Knop; Thure Krarup; A Johansen; Sten Madsbad; Steen Larsen; T Hansen; O Pedersen; Jens Juul Holst
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
The Journal of clinical endocrinology and metabolism 2003;88(10):4897-903.
2003: Filip K Knop; Tina Vilsbøll; Steen Larsen; Sten Madsbad; Jens J Holst; Thure Krarup
No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
Diabetes care 2003;26(9):2581-7.
2003: Filip K Knop; Mark Berner Hansen; Søren Meisner
Small-bowel hemangiosarcoma and capsule endoscopy.
Endoscopy 2003;35(7):637.